In conclusion, we have, for the first time, demonstrated that COTE1 is upregulated in ICC patients, and overexpression of COTE1 is associated with aggressive clinical features and predicts poor prognosis of ICC patients. This evidence concerns the gene ENTREP3 and intrahepatic cholangiocarcinoma.